October 21, 2019

To: Consensus Standards Approval Committee (CSAC)
From: Neurology Project Team
Re: Neurology Spring 2019 Review Cycle

CSAC Action Required
The CSAC will review recommendations from the Neurology Standing Committee at its October 21, 2019 meeting and vote on whether to uphold the recommendations from the Committee.

This memo includes a summary of the project, measure recommendation, themes identified and responses to the public and member comments and the results from the NQF member expression of support. The following documents accompany this memo:

1. Neurology Draft Report. The draft report has been updated to reflect the changes made following the Standing Committee’s discussion of public and member comments. The complete draft report and supplemental materials are available on the project webpage.
2. Comment Table. Staff has identified themes within the comments received. This table lists the four comments received during the post-meeting comment period and NQF’s responses.

Background
This NQF project aims to evaluate performance measures that will help guide quality improvement in the care and treatment of neurological conditions in the United States. This work is achieved by a structured review of quality measures by a 17-person Neurology Standing Committee. During this review cycle, the Committee reviewed one measure, #2872e Dementia – Cognitive Assessment.

Draft Report
The Neurology draft report presents the results of the evaluation of the one measure considered under the Consensus Development Process (CDP). The measure is recommended for endorsement.

The measure was evaluated against the 2018 version of the measure evaluation criteria.

<table>
<thead>
<tr>
<th></th>
<th>Maintenance</th>
<th>New</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measures under consideration</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Measures recommended for endorsement</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Measures recommended for inactive endorsement with reserve status</td>
<td>Maintenance</td>
<td>New</td>
<td>Total</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>-------------</td>
<td>-----</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Measures approved for trial use</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Measures not recommended for endorsement or trial use</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Measures withdrawn from consideration</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Reasons for not recommending</td>
<td>Importance - 0</td>
<td>Scientific Acceptability - 0</td>
<td>Use - 0</td>
</tr>
<tr>
<td></td>
<td>Scientific Acceptability - N/A</td>
<td>Use - N/A</td>
<td>Overall - 0</td>
</tr>
<tr>
<td></td>
<td>Competing Measure - 0</td>
<td>Overall - N/A</td>
<td>Competing Measure – N/A</td>
</tr>
</tbody>
</table>

**CSAC Action Required**

Pursuant to the CDP, the CSAC is asked to consider endorsement of one candidate consensus measure.

**Measure Recommended for Endorsement**

- 2872e Dementia – Cognitive Assessment (PCPI Foundation)

Overall Suitability for Endorsement: Yes-9; No-5

**Comments and Their Disposition**

NQF received four comments from three organizations (including two member organizations) and individuals pertaining to the draft report and to the measure under consideration.

A table of comments submitted during the comment period, with the responses to each comment and the actions taken by the Standing Committee and measure developer, is posted to the Neurology project webpage.

**Comment Themes and Committee Responses**

Comments about measure specifications and rationale were forwarded to the developer for their consideration.

The Standing Committee also received all comments in anticipation of the post-comment web meeting. During that meeting, staff guided the Standing Committee through the measure, prior voting summary, and through the public comments received and proposed NQF responses to those comments. That discourse is described below.
Measure-Specific Comments

2872e Dementia: Cognitive Assessment (PCPI Foundation)

All comments received supported the measure despite concerns expressed by NQF’s Standing Committee, with a single exception. One commenter did note that measurement burden is a concern thereby supporting, at least partially, the Standing Committee’s suggestion that a single measure of cognition may not be wise given the potential importance of simultaneously or alternatively assessing other aspects of functioning and mood. Moreover, NQF has deployed the criterion of “usability” which requires developers and evaluators to consider if a measure’s benefits exceed it costs.

One of the commenters expressed concern that the Committee did not reach a 66 percent quorum during the webinar when the measure was initially presented. In response, NQF noted that only a voting quorum, which can be achieved asynchronously, is required. NQF Standing Committee members are strongly encouraged to attend all web meetings, but when they are unable, they are given evaluation materials including meeting audio recordings which allow them to cast an informed vote after a meeting has occurred.

Commenters expressed concern that if the measure does not receive endorsement it may be eliminated from the Merit-Based Incentive Payment System and the Medicaid Promoting Interoperability program. In response to that NQF acknowledged this possibility, but further noted that the Committee’s favorable review was not based on specific program concerns other than the expectation that maintained measures must be deployed as part of our usability criteria.

Additionally, in an apparent effort to assuage Committee concerns that this measure was too narrow, the commenters described several other measures (most not NQF-endorsed) beyond cognitive assessment which are either in use by federal programs or have been developed to complement cognitive assessment. Those measures included metrics for dementia staging, neuropsychiatric symptoms, functional status, counseling for safety, and caregiver education and support. In response NQF expressed interest in these other measures and further suggested that in the future they be submitted jointly (as a composite) or separately for NQF review.

One public comment, actually put forward by the developer, provided a good description of the two Standing Committee concerns regarding the measure: (1) that the evidence linking the measure to quality outcomes was not persuasive, and (2) that cognitive assessment alone may be insufficient given that other forms of functioning including mood may be as, or more, important than cognition as a guide for therapeutic action. Regarding evidence, one commenter suggested an exception be considered for this measure because randomized trials of dementia disorders are especially challenging and impractical. In response to this comment, NQF staff acknowledged the challenges of conducting randomized control trials (RCTs) but reminded the developer that other forms of evidence were admissible as well, as long as those submissions were transparent including grading. Regarding cognitive assessment in isolation, commenters suggested that some members of the Committee were incorrect to suggest that other forms of assessment are more important. In response to the comment, NQF staff noted that Committee concerns were more that cognitive assessment, per se, might be incomplete or off-target as a chief therapeutic concern.
Finally, one commenter noted that cognition is an integral part of functional assessment and provided a reference to support that connection. NQF staff’s review of the article did not show this reference to be substantially illuminating.

---

Appendix A: CSAC Checklist

The table below lists the key considerations to inform the CSAC’s review of the measures submitted for endorsement consideration.

<table>
<thead>
<tr>
<th>Key Consideration</th>
<th>Yes/No</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were there any process concerns raised during the CDP project? If so, briefly explain.</td>
<td>Yes</td>
<td>Concerns from developer about absence of quorum given the number of Committee members who participated on the initial measure discussion call. Mitigated by not NQF’s asynchronous voting strategy.</td>
</tr>
<tr>
<td>Did the Standing Committee receive requests for reconsideration? If so, briefly explain.</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Did the Standing Committee overturn any of the Scientific Methods Panel’s ratings of Scientific Acceptability? If so, state the measure and why the measure was overturned.</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>If a recommended measure is a related and/or competing measure, was a rationale provided for the Standing Committee’s recommendation? If not, briefly explain.</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Were any measurement gap areas addressed? If so, identify the areas.</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Are there additional concerns that require CSAC discussion? If so, briefly explain.</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
Appendix B: NQF Member Expression of Support Results

One NQF member provided their expression of support

**2872e Dementia – Cognitive Assessment (PCPI Foundation)**

<table>
<thead>
<tr>
<th>Member Council</th>
<th>Support</th>
<th>Do Not Support</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Professional</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
Appendix D: Details of Measure Evaluation

Measure Recommended

2872e Dementia: Cognitive Assessment

Submission | Specifications

**Description:** Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

**Numerator Statement:** Patients for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

**Denominator Statement:** All patients, regardless of age, with a diagnosis of dementia

**Exclusions:** Documentation of patient reason(s) for not assessing cognition

**Adjustment/Stratification:** No risk adjustment or risk stratification Consistent with CMS’ Measures Management System Blueprint and recent national recommendations put forth by the IOM and NQF to standardize the collection of race and ethnicity data, we encourage the results of this measure to be stratified by race, ethnicity, administrative sex, and payer and have included these variables as recommended data elements to be collected.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual

**Setting of Care:** Inpatient/Hospital, Other, Outpatient Services

**Type of Measure:** Process

**Data Source:** Electronic Health Records

**Measure Steward:** PCPI Foundation

---

STANDING COMMITTEE MEETING 06/27/2019

1. Importance to Measure and Report: The measure meets the Importance criteria
(1a. Evidence, 1b. Performance Gap)

1a. Evidence: H-0; M-5; L-2; I-4; 1b. Performance Gap: H-4; M-6; L-0; I-1

Revote on September 11, 2019 Post-Comment Call

Evidence: H-1; M-9; L-0; I-4

Rationale:
- 2 CPGs were cited to support cognitive assessment for Dementia.
- The developer submitted the following:
  - updated evidence from the Alzheimer’s Association 2018 Dementia Care Practice Recommendations: Person-Centered Assessment and Care Planning.
  - Evidence from Examining models of dementia care (ASPE Final Report No. 0212704.017.000.001), which recommends and references guidelines and reports that consistently support cognitive screening as a best practice is provided.
• However, the lack of graded evidence from the guidelines presented along with a
general absence of empirical studies that connect cognitive assessment of dementia
cases to better outcomes for patients and their families, were cited as concerns for the
Standing Committee.
• The Committee noted that one useful result of deploying this measure is that it
encourages longitudinal (in this case annual) assessment of dementia.
• The Committee noted a significant performance gap that still exists especially for
underserved populations.
• During the post-comment call, the Committee opted to revote on the evidence criteria.
The votes landed in favor of passing the measure on the evidence presented. The
Committee decided to revote on evidence during the post-comment call because during
the initial measure evaluation web meeting in June, the evidence vote resulted in a
consensus not being met.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific
Acceptability criteria
(2a. Reliability - precise specifications, testing; 2b. Validity - testing, threats to validity
2a. Reliability: H-0; M-8; L-3; I-0; 2b. Validity: H-1; M-6; L-4; I-0
Rationale:
• Measure score-level reliability testing using data from Jan 2016 – Dec 2016 data for the
PQRS program is provided. Given the required conversion to ICD-10 in late 2015, the
testing was completed on the ICD-10 specified measure.
• Reliability testing provided on a total of 19,209 quality events for 511 providers.
• The developer showed that reliability and validity exist for group practices only. Thus,
the Committee could only consider group level of analysis for endorsement. Individual
practice level was not considered.
• The Committee noted that the exclusion provided is logical. No quantification of the
impact of the exclusion on performance was provided.
• The developer noted that the PQRS dataset provided by CMS did not contain missing
data so this test was not performed.
• The Committee also discussed limitations of correlation analysis, given the lack of an
appropriate gold standard. The Committee discussed whether depression and suicide
assessments were valid comparators for dementia assessment. In defense the
developer noted that these two comparator measures were eCQMs, like the measure
under consideration.

3. Feasibility: H-0; M-9; L-2; I-0
(3a. Clinical data generated during care delivery; 3b. Electronic sources; 3c. Susceptibility to
inaccuracies/ unintended consequences identified 3d. Data collection strategy can be
implemented)
Rationale:
• Data are collected through electronic health records and the two entities assessed were
not using a structured format for capturing feasibility, because exception information is
extracted from documentation within the medical record, explaining why the patient did not receive the standard of care.

- The Committee did not express concerns about the feasibility of the measure, since it has been successfully measured using electronic health record data for some time.

4. Use and Usability

4a. Use; 4a1. Accountability and transparency; 4a2. Feedback on the measure by those being measured and others; 4b. Usability; 4b1. Improvement; 4b2. The benefits to patients outweigh evidence of unintended negative consequences to patients)

4a. Use: **Pass-10; No Pass-1**; 4b. Usability: H-3; M-4; L-1; I-3

**Rationale:** Given the use of the measure as part of federal reporting, the Committee also did not express any concerns related to use and usability of the measure.

- The measure is currently used for public reporting and the Merit-based Incentive Payment System (MIPS).
- The developer noted they have not received reports of unexpected findings resulting from the implementation of this measure.
- The developer did not identify any unintended benefits for this measure during testing or since implementation.

5. Related and Competing Measures

- No related or competing measures noted.

6. Standing Committee Recommendation for Endorsement: **Y-9; N-5**

**Rationale:**

- The Committee noted that the main decision-making point for consideration will be the lack of empirical evidence demonstrating a probable causal linkage between assessment and the ultimate goal of optimizing dementia care.
- As a result of the post-comment call, Committee members recommend the measure for continued endorsement.

7. Public and Member Comment

NQF received four comments from two member organizations, one non-member organization, and one individual. The comments generally supported continued endorsement of the measure, but noted the following:

- that measurement burden is a concern, partially supporting the Committee’s suggestion that a single measure of cognition may not be wise, in part, because it encourages measurement fragmentation rather and a more efficient, unified approach.
- that the Committee attendance did not reach a 66 percent quorum during the webinar when the measure was presented (though a voting quorum was reach post-hoc).
- that cognition is an integral part of functional assessment and provided a reference to support that connection.
that if the measure does not receive endorsement it may be eliminated from the Merit-Based Incentive Payment System and the Medicaid Promoting Interoperability program.

that evidence in support of this particular measure is difficult to generate because an RCTs related to dementia care are difficult to conduct.

that some members of the Committee may believe that assessments other than cognition for dementia are more important.

8. Consensus Standards Approval Committee (CSAC) Vote: Y-X; N-X

9. Appeals
Neurology
Spring 2019 Review Cycle

CSAC Review and Endorsement

October 21, 2019
16 endorsed measures
  » 14 process measures*
  » 1 outcome measure
  » 1 resource use measure

<table>
<thead>
<tr>
<th></th>
<th>Process</th>
<th>Outcome/Resource Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke</td>
<td>14*</td>
<td>2</td>
</tr>
<tr>
<td>Dementia</td>
<td>2</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
<td>2</td>
</tr>
</tbody>
</table>

*six of these measures are NQF endorsed with reserve status
Standing Committee Recommendations

- One maintenance measure (an electronic clinical quality measure) recommended for endorsement
  - 2872e Dementia: Cognitive Assessment
  - This measure was not reviewed by the Scientific Methods Panel (SMP)
Overarching Issues

- Difficult to find evidence that affirms the connection between a relatively basic activity (e.g., symptom screening) and a targeted outcome (lower symptoms, better functioning).

- A measure is best cast only if it considers burden on patients and their families, not just the burden on the entity that has to report on the measure.

- An assessment of one symptom (e.g., cognition) may be important, but alternatively it may be less important than other symptoms (e.g., mood or basic functioning).
Committee made two notable observations about validity:

1. Finding a good “gold standard” is challenging, and this requires some flexibility and imagination by developers.
2. The assumption that an eMeasure needs validation from a separate eMeasure is too restrictive.

Committee is concerned about the scarcity of measures in NQF’s neurology pipeline.

Stroke, dementia, epilepsy, pain/headaches/migraines, numbness/weakness, delirium, movement disorders, spinal and brain trauma, stupor/coma/consciousness, sleep, vision/hearing, behavioral health issues.
Public and Member Comment and Member Expressions of Support

- Four comments received
  - *Mostly supportive of the measures under review*
    - One of the few dementia measures, in MIPS, acknowledges that it is an incomplete process measure

- One NQF member expression of support received
## Timeline and Next Steps

<table>
<thead>
<tr>
<th>Process Step</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSAC Review Period</td>
<td>October 8-October 28, 2019</td>
</tr>
<tr>
<td><strong>CSAC In-Person Meeting</strong></td>
<td><strong>October 21-22, 2019</strong></td>
</tr>
<tr>
<td>Appeals Period</td>
<td>October 30-November 28, 2019</td>
</tr>
</tbody>
</table>
Questions?

- Project team:
  - Debjani Mukherjee, Senior Director
  - Michael Abrams, Senior Director
  - Yetunde Ogungbemi, Project Manager

- Project webpage: [http://www.qualityforum.org/Neurology.aspx](http://www.qualityforum.org/Neurology.aspx)

- Project email address: [Neurology@qualityforum.org](mailto:Neurology@qualityforum.org)
Neurology, Spring 2019
Review Cycle: CDP
Report

DRAFT REPORT FOR CSAC REVIEW

October 21, 2019

This report is funded by the Department of Health and Human Services under contract HHSM-500-2017-000601 Task Order HHSM-500-T0001.
Contents

Executive Summary ........................................................................................................................................... 3
Introduction ......................................................................................................................................................... 4
NQF Portfolio of Performance Measures for Neurological Conditions .......................................................... 4
    Table 1. NQF Neurology Portfolio of Measures .......................................................................................... 4
Neurology Measure Evaluation .......................................................................................................................... 5
    Table 2. Neurology Measure Evaluation Summary ....................................................................................... 5
    Comments Received Prior to Committee Evaluation ..................................................................................... 5
    Comments Received After Committee Evaluation ......................................................................................... 5
    Overarching Issues ........................................................................................................................................... 6
    Summary of Measure Evaluation .................................................................................................................... 6
References ............................................................................................................................................................ 8
Appendix A: Details of Measure Evaluation ........................................................................................................ 9
    Measure Recommended .................................................................................................................................... 9
    2872e Dementia: Cognitive Assessment .......................................................................................................... 9
Appendix B: Neurology Portfolio—Use in Federal Programs ............................................................................. 13
Appendix C: Neurology Standing Committee and NQF Staff .......................................................................... 15
Appendix D: Measure Specifications ................................................................................................................ 17
    2872e Dementia: Cognitive Assessment .......................................................................................................... 17
Neurology, Spring 2019 Cycle

DRAFT REPORT FOR CSAC REVIEW

Executive Summary

Neurological conditions and injuries affect millions of Americans each year, taking a tremendous toll on patients, families, and caregivers. For example, strokes are the fifth leading cause of death in the United States and cost billions of dollars in treatment, rehabilitation, and lost wages.¹ Similarly, Alzheimer’s disease, the most common form of dementia, is the fifth leading cause of death for adults aged 65 to 85, with costs expected to rise to nearly $500 billion annually by 2040.²

The Neurology portfolio currently has 18 endorsed measures for neurological conditions addressing diagnosis, treatments, and procedures. The portfolio contains 16 measures for stroke which include six measures that are NQF-endorsed with reserve status, and two for dementia. Appendix B details the full portfolio of NQF-endorsed neurological measures.

For this project, the Neurology Standing Committee evaluated one maintenance eMeasure against NQF’s evaluation criteria under review.

- 2872e Dementia: Cognitive Assessment (PCPI Foundation)

The Committee recommended the eMeasure for continued endorsement.

A brief summary of the measure currently under review is included in the body of the report; a detailed summary of the Committee’s discussion and ratings of the criteria for the measure under review is in Appendix A.
Introduction

Neurological conditions and injuries affect millions of Americans each year and take a tremendous toll on patients, families, and caregivers. Additionally, billions of dollars are spent on treatment, rehabilitation, and lost or reduced earnings.

- Strokes are the fifth leading cause of death in the United States as well as a leading cause of disability. Each year, approximately 795,000 people suffer a stroke. Healthcare costs of stroke, including medications and missed days of work, are estimated at $34 billion annually.³

- Alzheimer’s disease is the most common form of dementia with an estimated 5 million Americans living with the disease. An estimated 14 million people will have Alzheimer’s by 2050. In 2010, the cost for Alzheimer’s disease reached nearly $215 billion and is projected to rise to more than $500 billion annually by 2040.⁴

This NQF project aims to evaluate performance measures that will help guide quality improvement in the care and treatment of neurological conditions. On June 27, 2019, NQF convened the multistakeholder Neurology Standing Committee composed of 17 individuals to evaluate one NQF-endorsed measure due for maintenance review.

NQF Portfolio of Performance Measures for Neurological Conditions

The Neurology Standing Committee (Appendix C) oversees NQF’s portfolio of Neurology measures (Appendix B) that includes measures for stroke and dementia. This portfolio contains 18 measures: 14 process measures and two outcome and resource use measures (see table below).

Table 1. NQF Neurology Portfolio of Measures

<table>
<thead>
<tr>
<th></th>
<th>Process</th>
<th>Outcome/Resource Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke</td>
<td>14*</td>
<td>2</td>
</tr>
<tr>
<td>Dementia</td>
<td>2</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
<td>2</td>
</tr>
</tbody>
</table>

*Six of these measures are currently NQF-endorsed with reserve status.

Other measures related to neurological conditions can be found in other portfolios, including Patient Safety, Cardiovascular, and Surgery. Moreover, given neurologists’ distinctive expertise to diagnose and treat persons with a broad and consequential constellation of illnesses and symptoms,⁷ the neurology portfolio will plausibly expand in subsequent submission cycles to the following general domains of medical care:

- Dizziness, vertigo
- Epilepsy
- Pain, headaches, migraines
- Numbness, weakness
- Delirium
• Movement disorders (Tremors, Parkinson, tics)
• Spinal cord or traumatic brain injuries
• Stupor, coma, consciousness, brain death
• Sleep
• Vision, hearing
• Drugs and alcohol effects
• Psychosis
• Autism

**Neurology Measure Evaluation**

On June 27, 2019 the Neurology Standing Committee evaluated one measure undergoing maintenance review against NQF’s **standard measure evaluation criteria**.

**Table 2. Neurology Measure Evaluation Summary**

<table>
<thead>
<tr>
<th>Measures under consideration</th>
<th>Maintenance</th>
<th>New</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measure recommended for endorsement</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reasons for not recommending</th>
<th>Importance – X</th>
<th>Scientific Acceptability – X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use – X</td>
<td>Overall Suitability – X</td>
<td>Competing Measure – X</td>
</tr>
</tbody>
</table>

**Comments Received Prior to Committee Evaluation**

NQF solicits comments on endorsed measures on an ongoing basis through the [Quality Positioning System (QPS)](https://www.qualitypositioningsystem.org). In addition, NQF solicits comments for a continuous 16-week period during each evaluation cycle via an online tool located on the project webpage. For this evaluation cycle, the commenting period opened on April 25, 2019 and closed June 19, 2019. As of June 27, NQF did not receive any member or public comments.

**Comments Received After Committee Evaluation**

The continuous 16-week public commenting period with NQF member support closed on August 26, 2019. Following the Committee’s evaluation of the measure under consideration, NQF received four comments from two member organizations, one non-member organization, and one individual pertaining to the draft report and to the measure under consideration. All comments have been summarized in Appendix A.

Throughout the 16-week continuous public commenting period, NQF members had the opportunity to express their support (‘support’ or ‘do not support’) for each measure submitted for endorsement.
consideration to inform the Committee’s recommendations. One NQF member provided their expression of support.

**Overarching Issues**

During the Standing Committee’s discussion of the dementia measure, some general ideas about quality measurement emerged. First, the Committee observed that it is difficult to find evidence that affirms the connection between a relatively basic activity (e.g., symptom screening) and a targeted outcome (lower symptoms, better functioning). The second idea was that a measure is best cast only if it considers burden on patients and their families, not just the burden on the entity that has to report on the measure. The third idea was that an assessment of one symptom (e.g., cognition) may be important, but alternatively it may be less important than other symptoms (e.g., mood or basic functioning).

Fourth, the Committee made two notable observations about validity: (1) finding a good “gold standard” is challenging, and this requires some flexibility and imagination by developers, and (2) the requirement that an e-measure needs validation from a separate e-measure may be too restrictive. Finally, the Committee was generally concerned about the scarcity of measures in NQF’s neurology pipeline, generally, and specifically for dementia measures as the portfolio presently has only two.

**Summary of Measure Evaluation**

The following brief summary of the measure evaluation highlights the major issues that the Committee considered. Details of the Committee’s discussion and ratings of the criteria for the measure are included in Appendix A.

**Dementia**

**2872e Dementia: Cognitive Assessment (PCPI Foundation): Recommended**

**Description**: Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period;

**Measure Type**: Process; **Level of Analysis**: Clinician : Group/Practice; **Setting of Care**: Inpatient/Hospital, Other, Outpatient Services; **Data Source**: Electronic Health Records

Most of the discussion on this measure focused on the importance criteria, as the Committee was concerned by the absence of graded evidence from the guidelines presented, and by the more general absence of empirical studies that connect cognitive assessment of dementia cases to better outcomes for patients and their families. Committee members expressed concern that cognitive assessment alone may miss more general functional and behavioral indicators that are critical to optimizing dementia care, especially as the disease progresses.

Discussion regarding gap, reliability, and feasibility was brief as the Committee was not concerned that any of these aspects of the application were deficient. With respect to validity, the Committee discussed whether depression and suicide assessments were validating comparators to dementia cognitive assessment. They also asked the developer to provide some information regarding the comparators. The developer noted that these two comparator measures were electronic clinical quality measures (eCQMs), like the measure under consideration, and such parallel comparison choices are encouraged by NQF submission standards. The developer also argued that both the comparators selected are
somewhat related to dementia assessment, though they could not explain why suicide screening had a markedly stronger validating correlation than depression assessment \( (r = 0.52 \text{ vs. } r = 0.26, \text{ respectively}) \). The Committee did not express concerns about the feasibility of the measure, since it has been successfully measured using electronic health record data for some time. Given the use of the measure as part of PQRS, the Committee also did not express any concerns related to use and usability of the measure.

Ultimately, a Committee member noted that a key voting decision would be deciding whether or not an exception to NQF’s usual evidentiary requirements should be allowed in this case based on two conditions: (1) that the measure demonstrates marked potential to improve care, and (2) that deployment of the measure is not likely to result in unintended and/or negative consequences. In fact, discussion surrounding this measure revealed two potential unintended consequences: (1) misplaced focus on cognition alone (at the expense of more general function or behavior), and (2) undue burden on patients who might not have time or otherwise want another assessment. The developer and a public commenter responded to the first concern by noting that the cognitive measure has historically been part of a set of assessment processes, and the developer addressed the second point by observing that they rarely have received any negative patient/family feedback about the use of the measure. Finally, it is notable that the Committee expressed some hesitancy to vote down this measure for the simple reason that the neurology portfolio currently has just one other measure in it which addresses dementia—and that the other measure focuses on a contraindicated treatment (antipsychotic use in dementia patients without psychosis), rather than a desirable one.

During the post-comment call, on September 11, the Committee opted to re-vote on the evidence criteria. Overall during that call, the Committee expressed interest in the measure, but with a strong desire to see it revised to include behavioral function and mood in addition to cognitive assessment. Committee members were informed by their own members that clinical trials for evaluating assessments is unlikely, and that federal efforts are moving to fuller assessments beyond cognition alone. The CARE tool was also mentioned and discussed as a comparator. This tool is currently in use and is somewhat broader than the measure discussed. That tool was further described as being like a mini-mental exam. After these points were discussed, the Committee was advised to vote on the measure “as specified.” They were also encouraged to express any and all ambivalence and recommendations to inform future measure development in this area.
References


Appendix A: Details of Measure Evaluation

Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable

Measure Recommended

2872e Dementia: Cognitive Assessment

Submission | Specifications

Description: Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

Numerator Statement: Patients for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

Denominator Statement: All patients, regardless of age, with a diagnosis of dementia

Exclusions: Documentation of patient reason(s) for not assessing cognition

Adjustment/Stratification: No risk adjustment or risk stratification Consistent with CMS’ Measures Management System Blueprint and recent national recommendations put forth by the IOM and NQF to standardize the collection of race and ethnicity data, we encourage the results of this measure to be stratified by race, ethnicity, administrative sex, and payer and have included these variables as recommended data elements to be collected.

Level of Analysis: Clinician : Group/Practice, Clinician : Individual

Setting of Care: Inpatient/Hospital, Other, Outpatient Services

Type of Measure: Process

Data Source: Electronic Health Records

Measure Steward: PCPI Foundation

STANDING COMMITTEE MEETING 06/27/2019

1. Importance to Measure and Report: The measure meets the Importance criteria

   (1a. Evidence, 1b. Performance Gap)

   1a. Evidence: H-0; M-5; L-2; I-4; 1b. Performance Gap: H-4; M-6; L-0; I-1

   Revote on September 11, 2019 Post-Comment Call

   Evidence: H-1; M-9; L-0; I-4

   Rationale:
   - 2 CPGs were cited to support cognitive assessment for Dementia.
   - The developer submitted the following:
     - updated evidence from the Alzheimer’s Association 2018 Dementia Care Practice Recommendations: Person-Centered Assessment and Care Planning.
     - Evidence from Examining models of dementia care (ASPE Final Report No. 0212704.017.000.001), which recommends and references guidelines and reports that consistently support cognitive screening as a best practice is provided.
• However, the lack of graded evidence from the guidelines presented along with a general absence of empirical studies that connect cognitive assessment of dementia cases to better outcomes for patients and their families, were cited as concerns for the Standing Committee.
• The Committee noted that one useful result of deploying this measure is that it encourages longitudinal (in this case annual) assessment of dementia.
• The Committee noted a significant performance gap that still exists especially for underserved populations.
• During the post-comment call, the Committee opted to revote on the evidence criteria. The votes landed in favor of passing the measure on the evidence presented. The Committee decided to revote on evidence during the post-comment call because during the initial measure evaluation web meeting in June, the evidence vote resulted in a consensus not being met.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria

(2a. Reliability - precise specifications, testing; 2b. Validity - testing, threats to validity)

2a. Reliability: H-0; M-8; L-3; I-0; 2b. Validity: H-1; M-6; L-4; I-0

Rationale:
• Measure score-level reliability testing using data from Jan 2016 – Dec 2016 data for the PQRS program is provided. Given the required conversion to ICD-10 in late 2015, the testing was completed on the ICD-10 specified measure.
• Reliability testing provided on a total of 19,209 quality events for 511 providers.
• The developer showed that reliability and validity exist for group practices only. Thus, the Committee could only consider group level of analysis for endorsement. Individual practice level was not considered.
• The Committee noted that the exclusion provided is logical. No quantification of the impact of the exclusion on performance was provided.
• The developer noted that the PQRS dataset provided by CMS did not contain missing data so this test was not performed.
• The Committee also discussed limitations of correlation analysis, given the lack of an appropriate gold standard. The Committee discussed whether depression and suicide assessments were valid comparators for dementia assessment. In defense the developer noted that these two comparator measures were eCQMs, like the measure under consideration.

3. Feasibility: H-0; M-9; L-2; I-0

(3a. Clinical data generated during care delivery; 3b. Electronic sources; 3c. Susceptibility to inaccuracies/unintended consequences identified 3d. Data collection strategy can be implemented)

Rationale:
• Data are collected through electronic health records and the two entities assessed were not using a structured format for capturing feasibility, because exception information is extracted from documentation within the medical record, explaining why the patient did not receive the standard of care.
• The Committee did not express concerns about the feasibility of the measure, since it has been successfully measured using electronic health record data for some time.
4. Use and Usability

4a. Use; 4a1. Accountability and transparency; 4a2. Feedback on the measure by those being measured and others; 4b. Usability; 4b1. Improvement; 4b2. The benefits to patients outweigh evidence of unintended negative consequences to patients

4a. Use: Pass-10; No Pass-1; 4b. Usability: H-3; M-4; L-1; I-3

Rationale: Given the use of the measure as part of federal reporting, the Committee also did not express any concerns related to use and usability of the measure.

- The measure is currently used for public reporting and the Merit-based Incentive Payment System (MIPS).
- The developer noted they have not received reports of unexpected findings resulting from the implementation of this measure.
- The developer did not identify any unintended benefits for this measure during testing or since implementation.

5. Related and Competing Measures

- No related or competing measures noted.

6. Standing Committee Recommendation for Endorsement: Y-9; N-5

Rationale:

- The Committee noted that the main decision-making point for consideration will be the lack of empirical evidence demonstrating a probable causal linkage between assessment and the ultimate goal of optimizing dementia care.
- As a result of the post-comment call, Committee members recommend the measure for continued endorsement.

7. Public and Member Comment

NQF received four comments from two member organizations, one non-member organization, and one individual. The comments generally supported continued endorsement of the measure, but noted the following:

- that measurement burden is a concern, partially supporting the Committee’s suggestion that a single measure of cognition may not be wise, in part, because it encourages measurement fragmentation rather and a more efficient, unified approach.
- that the Committee attendance did not reach a 66 percent quorum during the webinar when the measure was presented (though a voting quorum was reach post-hoc).
- that cognition is an integral part of functional assessment and provided a reference to support that connection.
- that if the measure does not receive endorsement it may be eliminated from the Merit-Based Incentive Payment System and the Medicaid Promoting Interoperability program.
- that evidence in support of this particular measure is difficult to generate because an RCTs related to dementia care are difficult to conduct.
• that some members of the Committee may believe that assessments other than cognition for dementia are more important.

8. Consensus Standards Approval Committee (CSAC) Vote: Y-X; N-X

9. Appeals
## Appendix B: Neurology Portfolio—Use in Federal Programs\(^a\)

*Measures currently endorsed with reserve status.

<table>
<thead>
<tr>
<th>NQF #</th>
<th>Title</th>
<th>Federal Programs: Finalized or Implemented as of May 31, 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>0434e*</td>
<td>STK 01: Venous Thromboembolism (VTE) Prophylaxis</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>0435e*</td>
<td>STK 02: Discharged on Antithrombotic Therapy</td>
<td>Medicare and Medicaid Electronic Health Record Incentive Program for Hospitals and Critical Access Hospitals</td>
</tr>
<tr>
<td>0436e*</td>
<td>STK 03: Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>Medicare and Medicaid Electronic Health Record Incentive Program for Hospitals and Critical Access Hospitals</td>
</tr>
<tr>
<td>0437</td>
<td>STK 04: Thrombolytic Therapy</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>0437e</td>
<td>STK 04: Thrombolytic Therapy</td>
<td>Hospital Inpatient Quality Reporting</td>
</tr>
<tr>
<td>0438e*</td>
<td>STK 05: Antithrombotic Therapy By End of Hospital Day Two</td>
<td>Medicare and Medicaid Electronic Health Record Incentive Program for Hospitals and Critical Access Hospitals</td>
</tr>
<tr>
<td>0439e*</td>
<td>STK 06: Discharged on Statin Medication</td>
<td>Medicare and Medicaid Electronic Health Record Incentive Program for Hospitals and Critical Access Hospitals</td>
</tr>
<tr>
<td>0441e*</td>
<td>STK 10: Assessed for Rehabilitation</td>
<td>Medicare and Medicaid Electronic Health Record Incentive Program for Hospitals and Critical Access Hospitals</td>
</tr>
<tr>
<td>0467</td>
<td>Acute Stroke Mortality Rate (IQI 17)</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>0507</td>
<td>Diagnostic Imaging: Stenosis Measurement in Carotid Imaging Reports</td>
<td>Merit-Based Incentive Payment System (MIPS) Program</td>
</tr>
<tr>
<td>0661</td>
<td>Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation within 45 minutes of ED Arrival</td>
<td>Hospital Compare; Hospital Outpatient Quality Reporting</td>
</tr>
<tr>
<td>1952</td>
<td>Time to Intravenous Thrombolytic Therapy</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>2111</td>
<td>Antipsychotic Use in Persons with Dementia</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>2863</td>
<td>CSTK-06: Nimodipine Treatment Administered</td>
<td>No federal program usage specified for this measure.</td>
</tr>
</tbody>
</table>

\(^a\) Per CMS Measures Inventory Tool as of 07/15/2019
<table>
<thead>
<tr>
<th>NQF #</th>
<th>Title</th>
<th>Federal Programs: Finalized or Implemented as of May 31, 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>2864</td>
<td>CSTK-01: National Institutes of Health Stroke Scale (NIHSS) Score Performed for Ischemic Stroke Patients</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>2866</td>
<td>CSTK-03: Severity Measurement Performed for Subarachnoid Hemorrhage (SAH) and Intracerebral Hemorrhage (ICH) Patients (Overall Rate)</td>
<td>No federal program usage specified for this measure.</td>
</tr>
<tr>
<td>2872e</td>
<td>Dementia: Cognitive Assessment</td>
<td>Merit-Based Incentive Payment System (MIPS) Program</td>
</tr>
<tr>
<td>2877e</td>
<td>Hybrid hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute ischemic stroke hospitalization with risk adjustment for stroke severity</td>
<td>No federal program usage specified for this measure.</td>
</tr>
</tbody>
</table>
Appendix C: Neurology Standing Committee and NQF Staff

STANDING COMMITTEE

David Knowlton, MA (Co-chair)
Retired
Pennington, New Jersey

David Tirschwell, MD, MSc (Co-chair)
University of Washington, Harborview Medical Center
Seattle, Washington

David Andrews
Georgia Regents Medical Center
Aiken, South Carolina

Jocelyn Bautista, MD
Cleveland Clinic Neurological Institute Epilepsy Center
Cleveland, Ohio

Ketan Bulsara, MD
Yale Department of Neurosurgery
New Haven, Connecticut

James Burke, MD
University of Michigan
Ann Arbor, Michigan

Michelle Camicia, MSN, RN, PHN, CRRN, CCM, FAHA
Kaiser Foundation Rehabilitation Center
Novato, California

Valerie Cotter, DrNP, AGPCNP-BC, FAANP
John Hopkins School of Nursing
Baltimore, Maryland

Bradford Dickerson, MD, MMSC
Massachusetts General Hospital
Charlestown, Massachusetts

Dorothy Edwards, PhD
University of Wisconsin Madison School of Medicine and Public Health
Madison, Wisconsin

Reuven Ferziger, MD
Merck and Company
Silver Spring, Maryland
Charlotte Jones, MD, PhD, MSPH
Food and Drug Administration
Silver Spring, Maryland

Michael Kaplitt, MD, PhD
Weill Cornell Medical College
New York, New York

Melody Ryan, PharmD, MPH
University of Kentucky College of Pharmacy
Lexington, Kentucky

Jane Sullivan, PT, DHS, MS
Northwestern University
Chicago, Illinois

Kelly Sullivan, PhD
Georgia Southern University
Statesboro, Georgia

Ross Zafonte, DO
Harvard Medical School
Boston, Massachusetts

NQF STAFF

Elisa Munthali, MPH
Senior Vice President, Quality Measurement

Debmani Mukherjee, MPH
Senior Director

Michael Abrams, MPH, PhD
Senior Director

Yetunde Ogungbemi, BS
Project Manager
Appendix D: Measure Specifications

2872e Dementia: Cognitive Assessment

STEWARD
   PCPI Foundation

DESCRIPTION
   Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

TYPE
   Process

DATA SOURCE
   Electronic Health Records Not applicable.

LEVEL
   Clinician : Group/Practice, Clinician : Individual

SETTING
   Inpatient/Hospital, Other, Outpatient Services Occupational Therapy Services, Domiciliary, Rest Home or Custodial Care Services

NUMERATOR STATEMENT
   Patients for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

NUMERATOR DETAILS
   Time Period for Data Collection: At least once during the measurement period

DEFINITION:
   Cognition can be assessed by the clinician during the patient's clinical history. Cognition can also be assessed by direct examination of the patient using one of a number of instruments, including several originally developed and validated for screening purposes. This can also include, where appropriate, administration to a knowledgeable informant. Examples include, but are not limited to:
   - Blessed Orientation-Memory-Concentration Test (BOMC)
   - Montreal Cognitive Assessment (MoCA)
   - St. Louis University Mental Status Examination (SLUMS)
   - Mini-Mental State Examination (MMSE) [Note: The MMSE has not been well validated for non-Alzheimer's dementias]
   - Short Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
   - Ascertain Dementia 8 (AD8) Questionnaire
- Minimum Data Set (MDS) Brief Interview of Mental Status (BIMS) [Note: Validated for use with nursing home patients only]
- Formal neuropsychological evaluation
- Mini-Cog

NUMERATOR GUIDANCE:
Use of a standardized tool or instrument to assess cognition other than those listed will meet numerator performance. Standardized tools can be mapped to the concept "Intervention, Performed": "Cognitive Assessment" included in the numerator logic below.
HQMF eCQM developed and is attached to this submission in fields S.2a and S.2b.

DENOMINATOR STATEMENT
All patients, regardless of age, with a diagnosis of dementia

DENOMINATOR DETAILS
Time Period for Data Collection: 12 consecutive months
DENOMINATOR GUIDANCE:
The requirement of two or more visits is to establish that the eligible professional or eligible clinician has an existing relationship with the patient.
The DSM-5 has replaced the term dementia with major neurocognitive disorder and mild neurocognitive disorder. For the purposes of this measure, the terms are equivalent.
HQMF eCQM developed and is attached to this submission in fields S.2a and S.2b.

EXCLUSIONS
Documentation of patient reason(s) for not assessing cognition

EXCLUSION DETAILS
Time Period for Data Collection: 12 consecutive months
Exceptions are used to remove a patient from the denominator of a performance measure when the patient does not receive a therapy or service AND that therapy or service would not be appropriate due to patient-specific reasons. The patient would otherwise meet the denominator criteria. Exceptions are not absolute, and are based on clinical judgment, individual patient characteristics, or patient preferences. The PCPI exception methodology uses three categories of reasons for which a patient may be removed from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. For measure Dementia: Cognitive Assessment, exceptions may include patient reason(s) for not assessing cognition. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement.
HQMF eCQM developed and is attached to this submission in fields S.2a and S.2b.
RISK ADJUSTMENT
No risk adjustment or risk stratification

STRATIFICATION
Consistent with CMS’ Measures Management System Blueprint and recent national recommendations put forth by the IOM and NQF to standardize the collection of race and ethnicity data, we encourage the results of this measure to be stratified by race, ethnicity, administrative sex, and payer and have included these variables as recommended data elements to be collected.

TYPE SCORE
Rate/proportion better quality = higher score

ALGORITHM
To calculate performance rates:
1. Find the patients who meet the initial population (ie, the general group of patients that a set of performance measures is designed to address).
2. From the patients within the initial population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial population and denominator are identical.
3. From the patients within the denominator, find the patients who meet the numerator criteria (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4. From the patients who did not meet the numerator criteria, determine if the provider has documented that the patient meets any criteria for exception when denominator exceptions have been specified [for this measure: patient reason(s) for not assessing cognition]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the exception rate (ie, percentage with valid exceptions) should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.
   If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. 140560| 135810| 141015